Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quetiapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.85 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.85 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.85 |
| ▸ | DRD3 | P35462 | 3/20 | 0.85 |
| ▸ | DRD4 | P21917 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.85 |
| ▸ | HTR1A | P08908 | 2/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.85 |
| ▸ | DRD1 | P21728 | 2/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.85 |
| ▸ | HRH1 | P35367 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quetiapine SCHEMBL29487500 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL122596 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL31678628 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL4962023 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL41336 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL390694 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL30990390 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5325208 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL41338 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5070765 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119607012-A | Application of Maitake mushroom polysaccharide D component or its derivative in preparing medicine for treating schizophrenia | 首都医科大学附属北京安定医院 | 2025-03-14 | — | — | CN | disclosed |
| US-12023340-B2 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC | 2024-07-02 | — | — | US | disclosed |
| CN-117821168-A | Semiconductor chip cleaning liquid, preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-114441663-A | Method for screening protein positive compounds by using solid phase microextraction affinity selection mass spectrum | 中国科学院上海药物研究所 | 2022-05-06 | — | — | CN | disclosed |
| US-10940155-B2 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200179399-A1 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | TLC THERAPEUTICS LLC (US) | 2020-06-11 | — | — | US | disclosed |
| US-10561669-B2 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180360844-A1 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | ROSEMONT PHARMACEUTICALS LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-9993486-B1 | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability | TLC THERAPEUTICS, LLC (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| WO-2006113914-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | DRD2 2994/4885HTR2A 3491/4885HTR2C 3906/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | DRD2 4261/4885HTR2A 1570/4885HTR2C 3099/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | DRD2 3570/4885HTR2A 1569/4885HTR2C 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.